Cutler Group LP Otonomy, Inc. Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	BUY	$1.72 - $2.51 $2,580 - $3,764	1,500 New	1,500 $3,000
Q4 2019 Feb 06, 2020	SELL	$2.13 - $3.83 $2,556 - $4,596	-1,200 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$4.05 - $6.1 $40,548 - $61,073	-10,012 Reduced 89.3%	1,200 $5,000
Q4 2017 Jan 17, 2018	SELL	$2.8 - $5.55 $2,486 - $4,928	-888 Reduced 7.34%	11,212 $62,000
Q3 2017 Oct 17, 2017	BUY	$3.2 - $20.8 $38,720 - $251,680	12,100	12,100 $39,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.